케이바이오랩스·휴럼·CNT85, 시가총액 미달로 상장 유지 위기
케이바이오랩스, 휴럼, CNT85 등 3개 상장사가 시가총액 기준을 밑돌아 관리종목 지정 여부를 앞두고 있다. 시가총액 미달이 이어지면 상장폐지될 수 있다는 안내가 나왔다.
Shareholder perspective 상장 유지에 직접 영향을 주는 개별 회사들의 시가총액 미달 문제로, 해당 기업 주주의 거래 가능성과 투자 회수 위험이 커질 수 있다.
Latest close needs updating · remaining observation days unconfirmed
At least 0 verified trading days elapsed
Projected dates assume continued shortfalls without trading suspensions from the next trading day. Weekends and holidays are excluded, and thresholds apply by date.
Recovering stocks are also assumed to fall below the threshold at the next close. The projected date is not a final delisting decision date; confirm official status and schedules in KRX disclosures.
Use the period buttons above to adjust the range.
Consolidated → separate financial data
From the 2019 annual report, the collected financial data uses a separate (individual) basis. Consolidated data is unavailable for these periods, so those cells are empty. See the separate table for the latest results.
Separate · this company only
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||
| Revenue | 146.5 × 100M KRW | 47.1 × 100M KRW | 173.5 × 100M KRW | 35.4 × 100M KRW | 152.9 × 100M KRW | 113.2 × 100M KRW | 72.2 × 100M KRW | 9 × 100M KRW | 386.3 × 100M KRW | 320.8 × 100M KRW | 501.7 × 100M KRW | 670.4 × 100M KRW | 475 × 100M KRW |
| Operating profit | -57.5 × 100M KRW | -15.6 × 100M KRW | 7.3 × 100M KRW | -27.5 × 100M KRW | 3.4 × 100M KRW | -52.2 × 100M KRW | -35 × 100M KRW | -47.6 × 100M KRW | -2.1 × 100M KRW | 15.3 × 100M KRW | 8.8 × 100M KRW | -14.1 × 100M KRW | -112.7 × 100M KRW |
| Net income | -181.7 × 100M KRW | -76.6 × 100M KRW | -107.2 × 100M KRW | -80.3 × 100M KRW | -215.2 × 100M KRW | -180 × 100M KRW | -314 × 100M KRW | -71.3 × 100M KRW | -50.1 × 100M KRW | 13.8 × 100M KRW | 83.7 × 100M KRW | -13.5 × 100M KRW | -126.6 × 100M KRW |
| Operating margin | -39.24% | -33.19% | 4.21% | -77.63% | 2.23% | -46.13% | -48.54% | -531.13% | -0.56% | 4.76% | 1.76% | -2.10% | -23.72% |
| Balance sheet | |||||||||||||
| Total assets | 398.8 × 100M KRW | 323.4 × 100M KRW | 371.7 × 100M KRW | 413.4 × 100M KRW | 661.6 × 100M KRW | 814.8 × 100M KRW | 281.9 × 100M KRW | 598.7 × 100M KRW | 639.7 × 100M KRW | 498.9 × 100M KRW | 1,075.9 × 100M KRW | 895.2 × 100M KRW | 850.9 × 100M KRW |
| Total liabilities | 288.3 × 100M KRW | 235.6 × 100M KRW | 198.5 × 100M KRW | 260.2 × 100M KRW | 333.9 × 100M KRW | 484 × 100M KRW | 313.3 × 100M KRW | 372.8 × 100M KRW | 457.4 × 100M KRW | 296.1 × 100M KRW | 352.9 × 100M KRW | 184.1 × 100M KRW | 266.3 × 100M KRW |
| Total equity | 110.5 × 100M KRW | 87.8 × 100M KRW | 173.1 × 100M KRW | 153.2 × 100M KRW | 327.8 × 100M KRW | 330.8 × 100M KRW | -31.3 × 100M KRW | 225.9 × 100M KRW | 182.3 × 100M KRW | 202.7 × 100M KRW | 723 × 100M KRW | 711.1 × 100M KRW | 584.6 × 100M KRW |
| Cash flow statement | |||||||||||||
| Operating cash flow | - | - | - | - | - | - | - | - | - | - | - | - | -83 × 100M KRW |
| Investing cash flow | - | - | - | - | - | - | - | - | - | - | - | - | 12.9 × 100M KRW |
| Financing cash flow | - | - | - | - | - | - | - | - | - | - | - | - | 23.5 × 100M KRW |
| Investment indicators | |||||||||||||
| ROE | -164.38% | -87.25% | -61.90% | -52.44% | -65.64% | -54.40% | 1001.51% | -31.58% | -27.50% | 6.79% | 11.57% | -1.90% | -21.66% |
| Debt-to-equity ratio | 260.88% | 268.37% | 114.68% | 169.85% | 101.85% | 146.31% | -999.35% | 165.07% | 250.92% | 146.07% | 48.81% | 25.89% | 45.55% |
| Separate total assets | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PER | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Detailed accounts | |||||||||||||
| Current assets | - | - | 104.8 × 100M KRW | - | - | 381.8 × 100M KRW | - | - | 230.9 × 100M KRW | - | - | 618.1 × 100M KRW | 618.4 × 100M KRW |
| Non-current assets | - | - | 266.9 × 100M KRW | - | - | 433 × 100M KRW | - | - | 408.8 × 100M KRW | - | - | 277.1 × 100M KRW | 232.5 × 100M KRW |
| Current liabilities | - | - | 132.8 × 100M KRW | - | - | 412 × 100M KRW | - | - | 432.6 × 100M KRW | - | - | 163 × 100M KRW | 253.9 × 100M KRW |
| Non-current liabilities | - | - | 65.8 × 100M KRW | - | - | 72 × 100M KRW | - | - | 24.8 × 100M KRW | - | - | 21.1 × 100M KRW | 12.4 × 100M KRW |
| Share capital | - | - | - | - | - | 230.8 × 100M KRW | - | - | 353.5 × 100M KRW | - | - | 370.6 × 100M KRW | 370.6 × 100M KRW |
| Capital surplus | - | - | - | - | - | - | - | - | - | - | - | - | 1,221.4 × 100M KRW |
| Other equity | - | - | - | - | - | - | - | - | - | - | - | - | -183.8 × 100M KRW |
| Accumulated other comprehensive income | - | - | - | - | - | - | - | - | - | - | - | - | -13.5 × 100M KRW |
| Retained earnings | - | - | -325.5 × 100M KRW | - | - | -578.7 × 100M KRW | - | - | -765.3 × 100M KRW | - | - | -683.5 × 100M KRW | -810 × 100M KRW |
ROE is net income divided by closing equity. PER and PBR are omitted when the accounting scope or price date is unverified.
| Category | Location | Use | Area | Book value | Assessed land value |
|---|---|---|---|---|---|
| Land Unverified | Location unknown | 투자부동산 | - | 104 × 100M KRW | 104 × 100M KRW |
| Building Unverified | Location unknown | 투자부동산 | - | 35 × 100M KRW | 35 × 100M KRW |
| Land Unverified | Location unknown | - | - | 18 × 100M KRW | - |
| Building Unverified | Location unknown | - | - | 7 × 100M KRW | - |
| Building Unverified | Location unknown | 재고자산 | - | 3,725 × 10,000 KRW | - |
| Auditor | Type | Term start | Term end | Tenure | D-day |
|---|---|---|---|---|---|
| 김태영 | Audit committee member | 2022.12.14 | 2025.12.14 | 3 years | Expired |
| 김영진 | Audit committee member | 2024.03.28 | 2026.03.28 | 2 years | Expired |
| 최우영 | Audit committee member | 2024.03.28 | 2027.03.26 | 2 years | D-123 |
| 이지하 | Audit committee member | 2025.12.12 | 2027.03.26 | 1 years | D-123 |
| 유현우 | Audit committee member | 2026.06.19 | 2027.03.26 | 1 years | D-123 |
| 류판석 | Audit committee member | 2025.12.12 | 2027.03.28 | 1 years | D-125 |
| Name | Position | Category | Age | Term end |
|---|---|---|---|---|
| 이지하 | 이사 | 독립이사 | Age 73 | D-123 |
| 이기주 | 사장 | Inside director | Age 56 | D-125 |
| 박승운 | 이사 | Other non-executive director | Age 55 | D-123 |
| 김영진 | 이사 | Other non-executive director | Age 54 | D-123 |
| 류판석 | 이사 | 독립이사 | Age 54 | D-125 |
| 유현우 | 이사 | 독립이사 | Age 39 | D-123 |
케이바이오랩스, 휴럼, CNT85 등 3개 상장사가 시가총액 기준을 밑돌아 관리종목 지정 여부를 앞두고 있다. 시가총액 미달이 이어지면 상장폐지될 수 있다는 안내가 나왔다.
Shareholder perspective 상장 유지에 직접 영향을 주는 개별 회사들의 시가총액 미달 문제로, 해당 기업 주주의 거래 가능성과 투자 회수 위험이 커질 수 있다.
CNT85가 자금 조달을 마치고 본업 중심의 생존 전략을 추진하는 가운데, 시가총액을 높일 방안으로 자사주 소각이 거론됐다. 회사는 자기주식 89만8670주를 보유하고 있다.
Shareholder perspective 특정 코스닥 상장사의 시가총액 미달 및 상장 유지 리스크와 자사주 정책이 연결된 사건이다. 자사주 소각 여부는 유통주식 수와 주주가치에 영향을 줄 수 있다.